BLCO · Bausch + Lomb
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $23.00
Note written ·
Price against the kill line
9.4% clear of its kill line on the 17 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 17 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $23.00, set on 16 November 2026. The shares are up 19.4% since the close; the S&P 500 is down 4.5% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $23.00, above RBC Capital's $23 target of 29 October 2026 (the highest of the post-results targets cited here), which would show the shares leading; or a signed agreement by Bausch Health to sell Bausch + Lomb outright.
Research onlyNot in the portfolio.
Catalyst
The business · as of
Bausch + Lomb sells contact lenses, lens-care products, eye vitamins and eye drops (Vision Care), cataract and refractive-surgery equipment and implants (Surgical), and prescription eye drugs (Pharmaceuticals) to consumers, eye doctors, hospitals and pharmacies worldwide. Revenue was $1,375 million in the quarter to 30 September 2026.
What is changing, and what follows · as of
- What is changing now
- On 28 October 2026 the company raised its 2026 adjusted EBITDA outlook to $1,090–1,140 million from $1,025–1,075 million, its third raise of the year. Two weeks earlier, on 12 October 2026, CEO Brent Saunders left.
- What follows for the company
- Third-quarter adjusted EBITDA rose to $325 million from $243 million, and the operating margin widened to 11.3% from 7.4%. Long-term debt of $5,017 million still cost $95 million in interest that quarter.
- What follows for its customers, suppliers and competitors
- Bausch Health (BHC), owner of about 87%, now holds a more valuable stake to sell or distribute as it cuts debt. Alcon (ALC), Cooper Companies (COO) and Johnson & Johnson (JNJ) face a rival whose Surgical sales grew 9% and Pharmaceuticals 11%.
What the price assumes · as of
At the 13 November 2026 close (filed inputs to 28 October 2026), the shares trade at 2.2 times sales (EV/sales) and 31.4 times operating profit (EV/EBIT), with a 3.3% free-cash-flow yield. The P/E is not meaningful after a $111 million four-quarter net loss. Those multiples hold only if revenue keeps growing near the 7.3% of the latest quarter while the operating margin widens well beyond its 11.3%.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 28 October 2026; valuation at the 17 November 2026 close
- Revenue, latest quarter ($M)
- 1,375
- Revenue, change on a year (%)
- +7.3
- Operating margin (%)
- 11.3
- Free cash flow, four quarters ($M)
- 252
- Net cash, cash less debt ($M)
- −4,504
- Enterprise value to sales (×)
- 2.2
- Enterprise value to operating income (×)
- 31.2
- Free-cash-flow yield (%)
- 3.4
All filed numbers
What Bausch + Lomb reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Operating margin (%) |
|---|---|---|---|
| first filed | 1,375 | +7.3 | 11.3 |
| first filed | 1,394 | +9.1 | 6.0 |
| first filed | 1,244 | +9.4 | 2.7 |
| first filed | 1,405 | +9.8 | 8.0 |
| first filed | 1,281 | +7.1 | 7.4 |
| first filed | 1,278 | +5.1 | −0.9 |
| Pre-tax income ($M) | 58.0 |
| Net income ($M) four quarters: −111 | 32.0 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +2.1 |
| Operating cash flow ($M) | 554 |
| Capital spending ($M) | 302 |
| Free cash flow ($M) | 252 |
| Cash and short-term investments ($M) | 513 |
| Debt ($M) long-term debt | 5,017 |
| Net cash, cash less debt ($M) | −4,504 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 1,147 |
| Inventory ($M) | 1,007 |
| Shareholders' equity ($M) | 6,439 |
| Market value ($M) | 7,447 |
| Enterprise value, market value plus net debt ($M) | 11,951 |
| Enterprise value to sales (×) | 2.2 |
| Enterprise value to operating income (×) | 31.2 |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 1.2 |
| Free-cash-flow yield (%) | 3.4 |
Short interest (FINRA, settled 30 October 2026, published 10 November 2026): 0.7% of shares outstanding sold short, 2.3 days of average trading to cover, +1.9% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 days | Not available yet | Not available yet |
| 12 months | Not available yet | Not available yet |
Linked companies · as of
- Competitors:
- ALC, COO, JNJ
The thesis
Bausch + Lomb's profit recovery is real. Still, the shares are more likely to lag the S&P 500 over the next three months. They rose 24.1% in three months to $21.09 on 13 November 2026, which puts them at or above most analysts' post-results targets. The company also has an interim chief executive, and its parent controls when and how the stake is separated. The fourth-quarter report and the first 2027 outlook, due early in 2027, are the next scheduled test.
The rating is Low because the main improvement is already in the price, and the remaining upside depends on an event with no date. The company's 28 October 2026 results showed adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, excluding acquired research) of $325 million, up from $243 million a year earlier. It also raised its full-year outlook for the third time in 2026. Since then, analysts have raised their targets only to $19–23. One firm downgraded the shares, and the chief accounting officer sold shares on the open market.
Bullish and bearish views on Bausch + Lomb Corporation
The bull case on Bausch + Lomb Corporation (BLCO), in brief: margins are widening quarter after quarter. The bear case: price has caught up with targets.
Bull case
- Margins are widening quarter after quarter. The operating margin was 11.3% in the quarter to 30 September 2026, against 7.4% a year earlier and 2.7% in the quarter to 31 March 2026, according to the company's 10-Q filings.
- Third guidance raise of 2026. On 28 October 2026 the company lifted its 2026 adjusted EBITDA outlook to $1,090–1,140 million from $1,025–1,075 million. It also lifted its revenue outlook to $5,450–5,550 million from $5,440–5,540 million (third-quarter results release).
- All three segments grew. Third-quarter revenue was $1,375 million, up 7% as reported and 8% in constant currency. Vision Care grew 5%, Surgical 9% and Pharmaceuticals 11% (third-quarter results release, 28 October 2026).
- The parent still intends to separate. Bausch Health's 10-Q for the quarter to 30 September 2026 says it holds about 87% of Bausch + Lomb. It lists a sale of some or all of that stake, a distribution of shares to its own holders, or a mix of the two as possible routes. A whole-company sale at a premium is the main way the shares could beat the index.
Bear case
- Price has caught up with targets. After the results, Wells Fargo set a $19 target and JPMorgan $22 on 29 October 2026, and RBC Capital $23 the same day. HC Wainwright cut its rating to Neutral on 2 November 2026 while raising its target to $22 from $21.
- Leadership gap at the top. CEO Brent Saunders left on 12 October 2026 by mutual agreement with the board, and no reason was given. Chairman Thomas Appio became interim CEO while remaining CEO of Bausch Health. No timeline for a permanent appointment has been announced.
- Separation depends on the parent's debt. Bausch Health's third-quarter 10-Q ties any separation to reaching target debt ratios and obtaining approvals. Bausch Health also weighs its Xifaxan generic-drug litigation in deciding what to do with the stake. On Bausch Health's 28 October 2026 call, Appio said "nothing has changed" in what it had communicated before.
- Insiders and a known investor sold. SEC Form 4 filings show the chief accounting officer exercised options on 112,015 shares and sold all 112,015 at $20.48 on 29 October 2026. Benzinga reported on 13 November 2026 that Carl Icahn cut his stake by 32% to 2,378,100 shares.
- Heavy debt and thin earnings. On 30 September 2026 the company had $5,017 million of long-term debt and $513 million of cash. Third-quarter interest expense was $95 million. Net income over the four quarters to 30 September 2026 was a loss of $111 million.
Price setup
The shares closed at $21.09 on 13 November 2026. That is 1.4% below the 52-week intraday high of $21.40, set on 10 November 2026, when the stock closed at $21.37. The close compares with $17.00 on 17 August 2026 and a 52-week closing low of $14.56 on 20 November 2025. On adjusted daily closes, the price sits above the 50-day moving average of $17.98 and the 200-day moving average of $16.85, both as of 13 November 2026.
The latest gains came in two sessions. The stock closed at $19.99 on 6 November 2026 and $20.96 on 9 November 2026, with no company news dated to those sessions. The close is now inside the $19–23 range of post-results analyst targets, near its top. A common market view is that shares at a 52-week high keep leading. The rating does not rest on that view, and no reliable effect has been found so far for strong stocks after large moves.
Catalysts ahead
- ~25 February 2027 (est.): Fourth-quarter 2026 results and first 2027 outlook. This report shows whether the margin gains continue into 2027. An outlook that lifts adjusted EBITDA growth above the 2026 pace would undercut the lag call.
What would change the view
A daily close above $23.00, above RBC Capital's $23 target of 29 October 2026 (the highest of the post-results targets cited here), which would show the shares leading; or a signed agreement by Bausch Health to sell Bausch + Lomb outright.
What it trades with
The shares trade mainly on news from Bausch Health (BHC), which owns about 87% of them. That makes this an event-driven stock: Bausch Health's debt reduction, its Xifaxan litigation and any word on a sale or distribution move it more than sector news does. Day to day, the business competes in contact lenses and eye surgery with Alcon (ALC), Cooper Companies (COO) and Johnson & Johnson (JNJ). Currency matters: the 2026 outlook assumes a $40 million revenue boost from foreign exchange. The company says its guidance assumes it can offset 2026 tariff costs under current policy. With $5,017 million of long-term debt, borrowing costs feed directly into earnings.
Caveats
- Bausch + Lomb is controlled by Bausch Health, which holds about 87% of its shares and decides whether and how to sell or distribute the stake. Bausch Health Form 10-Q for the quarter ended 30 September 2026 · as of
- The interim CEO, Thomas Appio, also serves as chief executive of the controlling shareholder, Bausch Health. Bausch + Lomb Form 8-K filed 13 October 2026 · as of
The evidence, claim by claim (8)
- Third-quarter revenue was $1,375 million, up 7% as reported and 8% in constant currency. Vision Care was $774 million, Surgical $234 million and Pharmaceuticals $367 million. Bausch + Lomb third-quarter 2026 results release (Form 8-K, exhibit 99.1) · as of
- Adjusted EBITDA excluding acquired research was $325 million, against $243 million a year earlier. Net income attributable to the company was $32 million, against a $28 million loss. Bausch + Lomb third-quarter 2026 results release (Form 8-K, exhibit 99.1) · as of
- The 2026 outlook was raised to revenue of $5,450–5,550 million and adjusted EBITDA of $1,090–1,140 million, from $5,440–5,540 million and $1,025–1,075 million. Bausch + Lomb third-quarter 2026 results release (Form 8-K, exhibit 99.1) · as of
- CEO Brent Saunders stepped down. Chairman Thomas Appio was named interim CEO and remains CEO of Bausch Health. Bausch + Lomb Form 8-K; Fierce Pharma report · as of
- Bausch Health holds about 87% of Bausch + Lomb. Any separation through a sale, a distribution or both depends on reaching target debt ratios and obtaining approvals. Bausch Health Form 10-Q for the quarter ended 30 September 2026 · as of
- Chief accounting officer Frederick Munsch exercised options on 112,015 shares and sold 112,015 shares on the open market at $20.48. SEC Form 4 filed 2 November 2026 · as of
- HC Wainwright cut its rating to Neutral from Buy and raised its target to $22 from $21. HC Wainwright note reported by Benzinga, 2 November 2026 · as of
- Carl Icahn cut his Bausch + Lomb stake by 32%, to 2,378,100 shares. Benzinga report, 13 November 2026 · as of
Sources
- Bausch & Lomb Corp - Form 8-K - FY2026 · sec.gov ·
- Bausch Health Companies Inc. - Form 10-Q - FY2026 · sec.gov
- Bausch + Lomb names Appio interim CEO as Saunders hits the exit again · fiercepharma.com
- Bausch Health (BHC) Q3 2026 Earnings Call Transcript · fool.com ·
- Bausch + Lomb Posts Strong Third Quarter Results, Raises Full-Year Guidance · visionmonday.com
Related · shared themes
CDNA
CareDx
CareDx's shares are modestly more likely than not to beat the S&P 500: transplant testing revenue grew 39% in the third quarter excluding…
ONT
Onterris
Onterris's shares trade on a board-led strategic review that has engaged outside buyers and on a third-quarter cash flow recovery; a review…
GRAL
GRAIL
GRAIL's shares are more likely to lag the S&P 500 over three months: after a 78.8% three-month rise, approval of the Galleri cancer test…
OBIO
Orchestra BioMed Holdings
Orchestra BioMed is modestly more likely to lead the S&P 500 over three months: the November offering funds it through 2028 and analysts…